By AuntMinnie.com staff writers

October 9, 2015 -- MR-guided focused ultrasound (MRgFUS) developer InSightec has received U.S. Food and Drug Administration (FDA) clearance for a new version of its ExAblate device and a change in labeling.

The new version of system is cleared for the treatment of symptomatic uterine fibroids, and with the updated labeling, fibroid tissue ablation can now be considered for patients who wish to retain fertility, the company said.

BCBS updates coverage for InSightec's MRgFUS
MR-guided focused ultrasound (MRgFUS) developer InSightec announced that various Blue Cross/Blue Shield (BCBS) networks have updated coverage policies...
InSightec set to bring ExAblate to Japan
MR-guided focused ultrasound (MRgFUS) developer InSightec has received approval from Japan's Ministry of Health, Labor, and Welfare for its ExAblate MRgFUS...
InSightec lands insurance coverage for ExAblate
MR-guided focused ultrasound developer InSightec announced that Health Care Service has updated its coverage policy to include InSightec's ExAblate procedure...
Chinese investment group buys stake in InSightec
InSightec has received an investment of $12.5 million from Shanghai GEOC Hengtong Investment Limited Partnership and Fortune China Limited.
InSightec nets $50M investment
MR-guided focused ultrasound developer InSightec said it is raising $50 million in capital funding.

Copyright © 2015 AuntMinnie.com